SCHEMBL6692377

SCHEMBL6692377

COc1ccc(Oc2c(Cl)c(F)nc(F)c2Cl)cc1S(=O)(=O)Nc1ccc(F)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.58
▸ SMN1; SMN2 Q16637 7/20 0.55
▸ HTT P42858 2/20 0.55
▸ HPGD P15428 2/20 0.53
▸ MEN1 O00255 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ GLA P06280 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ CYP2D6 P10635 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ PKM P14618 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ RECQL P46063 1/20 0.53
▸ ALOX12 P18054 1/20 0.53
▸ TP53 P04637 1/20 0.52
▸ ALPL P05186 4/20 0.50
▸ NPSR1 Q6W5P4 2/20 0.50
▸ THRB P10828 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6697630 0.89 LMNA (0.55) LMNASMN1; SMN2HTTHPGDMEN1
SCHEMBL6690024 0.87 SMN1; SMN2 (0.48) LMNASMN1; SMN2HTTHPGDMEN1
SCHEMBL7536903 0.81 LMNA (0.75) LMNASMN1; SMN2HTTHPGDMEN1
SCHEMBL6692435 0.81 SMN1; SMN2 (0.39) LMNASMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL7262694 0.79 LMNA (0.58) LMNASMN1; SMN2HTTHPGDMEN1
SCHEMBL7571589 0.78 LMNA (0.73) LMNASMN1; SMN2HTTHPGDMEN1
SCHEMBL6694244 0.76 THRB (0.41) LMNASMN1; SMN2HPGDALDH1A1NPSR1
SCHEMBL6693291 0.76 THRB (0.38) LMNASMN1; SMN2HPGDMEN1KMT2A
SCHEMBL22095987 0.75 SMN1; SMN2 (0.78) LMNASMN1; SMN2HTTHPGDMEN1
SCHEMBL7529463 0.74 TP53 (0.80) LMNASMN1; SMN2HTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6747048-B2 TREATING DISEASES OR DISORDERS ASSOCIATED WITH METABOLISM DYSFUNCTION OR WHICH ARE DEPENDENT UPON THE EXPRESSION OF A T3 REGULATED GENE, BRISTOL-MYERS SQUIBB COMPANY 2004-06-08 — — US disclosed
US-20040039028-A1 Pyridine-based thyroid receptor ligands BRISTOL-MYERS SQUIBB COMPANY 2004-02-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039028-A1 Pyridine-based thyroid receptor ligands TSHR, THRB, THRA LMNA 4794/4885SMN1; SMN2 3943/4885HTT 4269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback